FDA Advisers Overwhelmingly Approve Carvykti and Abecma for Earlier Treatment Options

Washington, D.C. – A recent update on FDA advisers’ decisions regarding J&J and Legend’s Carvykti and BMS’ Abecma has sparked discussions in the medical community. Despite initial concerns about potential adverse effects leading to earlier deaths, the FDA advisers have ultimately backed these medications for a wider range of use. Carvykti and Abecma, two innovative treatments, have shown promising results in managing certain health conditions. The decision to support these drugs for earlier administration signifies …

Read more

FDA Panel Overwhelmingly Supports CAR-T Therapies for Multiple Myeloma Treatment

Silver Spring, Maryland – The FDA’s Oncologic Drugs Advisory Committee discussed the risks and benefits of CAR-T therapies developed by Johnson & Johnson, Legend Biotech, Bristol Myers Squibb, and 2seventyBio for the treatment of multiple myeloma. The committee voted in support of Carvykti and Abecma as earlier lines of treatment, despite concerns about early deaths in the trials. During the meeting, experts evaluated the data from the trials, noting a higher rate of early deaths …

Read more